TRVI

Trevi Therapeutics, Inc. (TRVI) | Rumor.io

Trevi Therapeutics

TRVI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,106

Bullish sentiment (50-day avg)1%

Price to earnings ratio-45

Market capitalization2.1B

Earnings per share-0.35

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-42.8M

Social

What share of all stock conversation is about TRVI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Jul 17

Trevi Therapeutics ($TRVI) has a development angle in IPF cough, but its opioid baggage is a concern.
$TRVI's price action shows a strong long-term uptrend with consistent higher highs and higher lows, currently in a consolidation phase.
Trevi Therapeutics' Haduvio (oral nalbuphine ER) is a promising therapy for chronic cough, with a recent development milestone as $GSK drops camlipixant due to disappointing data.

Generated by AI

Sentiment

Of the messages about TRVI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	68.92% -23.29
Bearish	—	—	—	31.08% +23.29

Bullish· Mar 11

$TRVI is expected to explode soon, with institutional buy coming in heavy and a potential price target of $20.
The stock has shown significant volume spikes, with 57.7M shares traded on March 10, and is primed to break out with analyst price target raises.
$TRVI has a strong 1-5 year chart, with very hard to find a bearish stance, and is likely to see easy gains with all new target raises.

Bearish· Mar 10

$TRVI has a weak financial position with a net loss of -$38.8 million and EPS of -$0.39, indicating a dilutive and non-profitable business model.
TRVI is heavily reliant on external funding due to its ongoing R&D and operational costs, and may run out of cash unless it secures additional financing.
The company's stock is subject to heavy dependence on fundraising and stock dilution risk, as evidenced by its recent $50 million underwritten offering, which may negatively impact existing shareholders.

Generated by AI

Topics

Of the messages about TRVI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	60.3%
Technical Analysis	—	0%	0%	15.76%
Analysts	—	0%	0%	16.67%
Controversies	—	0%	0%	0.3%
Earnings	—	0%	0%	1.82%
Macro	—	0%	0%	5.15%

Announcements· Mar 8

Trevi Therapeutics, Inc. (TRVI) announced a notice of allowance for a US patent application covering the use of Haduvio (nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis.
The patent application has an anticipated expiration in 2039 and covers the method of treatment of chronic cough in IPF with Haduvio.
Trevi stock rose on the news, with the company's shares increasing by 12.06% to $2.23 in the last 10 minutes.

Technical Analysis· Dec 12

$TRVI has broken VWAP and is showing great price action, with a whole dollar breakout and half dollar resistance.
$TRVI is testing support around $3.80 and resistance around $4.25, with potential for a breakout or breakdown.
$TRVI has shown impressive progress, up 10-25% since being identified, with clear signs of momentum and potential for further gains.

Generated by AI

Community

Of the messages about TRVI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	57.69%
Newcomers	0%	0%	0%	42.31%

Regulars· Sep 19

Trevi Therapeutics announces positive data from the full set of subjects in its Phase 2 CANAL Trial of Haduvio in the treatment of chronic cough in idiopathic pulmonary fibrosis, with statistically significant daytime cough reduction in adults with IPF (p
The results, including safety and efficacy, will be discussed in detail during a virtual R&D Day, and a corporate presentation from September 2022 is available.
Trevi Therapeutics' stock price has experienced a 12.63% decline to $3.39 in the last 18 minutes, with 36k shares traded at an average volume of 197k.

Newcomers· Jul 17

Newcomers are focused on the potential of Trevi Therapeutics' Haduvio (oral nalbuphine ER) as a treatment for chronic cough, following GSK's decision to drop development of a similar drug.
The stock's strong long-term uptrend is being discussed, with a recent rally from $5.38 to a new 52-week high of $20.15, and key levels to watch for resistance.
The GSK announcement has led to a significant price increase in Trevi Therapeutics, with the stock rising by +12.21% as investors react to the potential opportunity for Haduvio.

Generated by AI

News

Trevi Therapeutics to Participate in Upcoming September Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global He

26d agoYahoo Finance

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a

1mo agoYahoo Finance

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)

1mo agoSeeking Alpha

Also Discussed

Investors talking about TRVI also mention

#	Name	Attention
1	Werewolf Therapeutics Inc.HOWL	0%0
2	Relay Therapeutics Inc.RLAY	0%new
3	MDVL - MedAvail Holdings, Inc.	——
4	Edgewise Therapeutics Inc.EWTX	0%new
5	Momentus Inc. Class A Common StockMNTS	0%+0
6	UFP Technologies Inc.UFPT	0%0
7	Sunshine Biopharma Inc.SBFM	0%0
8	Nurix Therapeutics, Inc.NRIX	0%new
9	MeiraGTx Holdings plcMGTX	0%new
10	Insight Enterprises, Inc.NSIT	0%0

Trevi Therapeutics, Inc.

Healthcare
Biotechnology

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing investigational therapies for serious neurologically mediated conditions. Its lead program, Haduvio, is an oral extended-release formulation of nalbuphine designed to address chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The company also works on therapies for chronic pruritus and other conditions where opioid receptor modulation may help control symptoms. Trevi Therapeutics serves the specialty respiratory and neurology-adjacent treatment markets, with a business model centered on advancing targeted drug candidates through clinical development and toward potential commercialization. Based in New Haven, Connecticut, Trevi Therapeutics, Inc. focuses on unmet needs in chronic symptom management and operates within the broader biopharmaceutical innovation sector.

Website

Location

195 Church Street

New Haven, CT, 06510

United States

Social

What share of all stock conversation is about TRVI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Jul 17

Trevi Therapeutics ($TRVI) has a development angle in IPF cough, but its opioid baggage is a concern.
$TRVI's price action shows a strong long-term uptrend with consistent higher highs and higher lows, currently in a consolidation phase.
Trevi Therapeutics' Haduvio (oral nalbuphine ER) is a promising therapy for chronic cough, with a recent development milestone as $GSK drops camlipixant due to disappointing data.

Generated by AI

Sentiment

Of the messages about TRVI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	68.92% -23.29
Bearish	—	—	—	31.08% +23.29

Bullish· Mar 11

$TRVI is expected to explode soon, with institutional buy coming in heavy and a potential price target of $20.
The stock has shown significant volume spikes, with 57.7M shares traded on March 10, and is primed to break out with analyst price target raises.
$TRVI has a strong 1-5 year chart, with very hard to find a bearish stance, and is likely to see easy gains with all new target raises.

Bearish· Mar 10

$TRVI has a weak financial position with a net loss of -$38.8 million and EPS of -$0.39, indicating a dilutive and non-profitable business model.
TRVI is heavily reliant on external funding due to its ongoing R&D and operational costs, and may run out of cash unless it secures additional financing.
The company's stock is subject to heavy dependence on fundraising and stock dilution risk, as evidenced by its recent $50 million underwritten offering, which may negatively impact existing shareholders.

Generated by AI

Topics

Of the messages about TRVI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	60.3%
Technical Analysis	—	0%	0%	15.76%
Analysts	—	0%	0%	16.67%
Controversies	—	0%	0%	0.3%
Earnings	—	0%	0%	1.82%
Macro	—	0%	0%	5.15%

Announcements· Mar 8

Trevi Therapeutics, Inc. (TRVI) announced a notice of allowance for a US patent application covering the use of Haduvio (nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis.
The patent application has an anticipated expiration in 2039 and covers the method of treatment of chronic cough in IPF with Haduvio.
Trevi stock rose on the news, with the company's shares increasing by 12.06% to $2.23 in the last 10 minutes.

Technical Analysis· Dec 12

$TRVI has broken VWAP and is showing great price action, with a whole dollar breakout and half dollar resistance.
$TRVI is testing support around $3.80 and resistance around $4.25, with potential for a breakout or breakdown.
$TRVI has shown impressive progress, up 10-25% since being identified, with clear signs of momentum and potential for further gains.

Generated by AI

Community

Of the messages about TRVI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	57.69%
Newcomers	0%	0%	0%	42.31%

Regulars· Sep 19

Trevi Therapeutics announces positive data from the full set of subjects in its Phase 2 CANAL Trial of Haduvio in the treatment of chronic cough in idiopathic pulmonary fibrosis, with statistically significant daytime cough reduction in adults with IPF (p
The results, including safety and efficacy, will be discussed in detail during a virtual R&D Day, and a corporate presentation from September 2022 is available.
Trevi Therapeutics' stock price has experienced a 12.63% decline to $3.39 in the last 18 minutes, with 36k shares traded at an average volume of 197k.

Newcomers· Jul 17

Newcomers are focused on the potential of Trevi Therapeutics' Haduvio (oral nalbuphine ER) as a treatment for chronic cough, following GSK's decision to drop development of a similar drug.
The stock's strong long-term uptrend is being discussed, with a recent rally from $5.38 to a new 52-week high of $20.15, and key levels to watch for resistance.
The GSK announcement has led to a significant price increase in Trevi Therapeutics, with the stock rising by +12.21% as investors react to the potential opportunity for Haduvio.

Generated by AI

Trevi Therapeutics

Social

Jul 17

Bullish· Mar 11

Bearish· Mar 10

Announcements· Mar 8

Technical Analysis· Dec 12

Regulars· Sep 19

Newcomers· Jul 17

Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update

Trevi Therapeutics at cantor global healthcare conference: central cough bet

Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value

Trevi Therapeutics to Participate in Upcoming September Conferences

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)

Also Discussed

Trevi Therapeutics, Inc.

Company Information

Location

Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update

Trevi Therapeutics at cantor global healthcare conference: central cough bet

Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value

Trevi Therapeutics to Participate in Upcoming September Conferences

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)

Also Discussed

Social

Jul 17

Bullish· Mar 11

Bearish· Mar 10

Announcements· Mar 8

Technical Analysis· Dec 12

Regulars· Sep 19

Newcomers· Jul 17